Otonomy, Inc. Logo
Otonomy Completes Enrollment in Phase 2 Clinical Trial for AuriPro(TM) in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
May 07, 2015 07:00 ET | Otonomy, Inc.
SAN DIEGO, May 7, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy to Present at Two Upcoming Investor Conferences
May 06, 2015 07:30 ET | Otonomy, Inc.
SAN DIEGO, May 6, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Appoints George Morrow to Board of Directors
April 30, 2015 07:30 ET | Otonomy, Inc.
SAN DIEGO, April 30, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Announces FDA Acceptance of AuriPro(TM) New Drug Application
April 28, 2015 07:00 ET | Otonomy, Inc.
SAN DIEGO, April 28, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy to Present AuriPro(TM) Phase 3 Results at American Society of Pediatric Otolaryngology Conference
April 21, 2015 07:30 ET | Otonomy, Inc.
SAN DIEGO, April 21, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere's Disease Patients
April 20, 2015 07:30 ET | Otonomy, Inc.
SAN DIEGO, April 20, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Achieves Patient Enrollment Target in Phase 2b Clinical Trial of OTO-104 in Meniere's Disease
December 01, 2014 07:00 ET | Otonomy, Inc.
SAN DIEGO, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy to Present at the Piper Jaffray Healthcare Conference
November 20, 2014 08:30 ET | Otonomy, Inc.
SAN DIEGO, Nov. 20, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Reports Third Quarter 2014 Financial Results and Provides Corporate Update
November 12, 2014 16:05 ET | Otonomy, Inc.
SAN DIEGO, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Enrolls First Meniere's Disease Patients in OTO-104 Multiple-Dose Safety Study
October 09, 2014 07:30 ET | Otonomy, Inc.
SAN DIEGO, Oct. 9, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...